| Mir-34: a new weapon against cancer? G Misso, MT Di Martino, G De Rosa, AA Farooqi, A Lombardi, V Campani, ... Molecular therapy-nucleic acids 3, e195, 2014 | 449 | 2014 |
| Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma M Fulciniti, P Tassone, T Hideshima, S Vallet, P Nanjappa, SA Ettenberg, ... Blood, The Journal of the American Society of Hematology 114 (2), 371-379, 2009 | 399 | 2009 |
| BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells P Tassone, P Tagliaferri, A Perricelli, S Blotta, B Quaresima, ML Martelli, ... British journal of cancer 88 (8), 1285-1291, 2003 | 390 | 2003 |
| Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 … A Chan, S Delaloge, FA Holmes, B Moy, H Iwata, VJ Harvey, NJ Robert, ... The Lancet Oncology 17 (3), 367-377, 2016 | 378 | 2016 |
| Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells L Catley, E Weisberg, T Kiziltepe, YT Tai, T Hideshima, P Neri, P Tassone, ... Blood 108 (10), 3441-3449, 2006 | 367 | 2006 |
| HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells E Carbone, P Neri, M Mesuraca, MT Fulciniti, T Otsuki, D Pende, V Groh, ... Blood 105 (1), 251-258, 2005 | 341 | 2005 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 339 | 2017 |
| Dysfunctional T regulatory cells in multiple myeloma RH Prabhala, P Neri, JE Bae, P Tassone, MA Shammas, CK Allam, ... Blood 107 (1), 301-304, 2006 | 249 | 2006 |
| Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence MT Di Martino, E Leone, N Amodio, U Foresta, M Lionetti, MR Pitari, ... Clinical cancer research 18 (22), 6260-6270, 2012 | 212 | 2012 |
| Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy P Correale, MS Rotundo, MT Del Vecchio, C Remondo, C Migali, ... Journal of immunotherapy (Hagerstown, Md.: 1997) 33 (4), 435, 2010 | 211 | 2010 |
| Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines P Tassone, S Forciniti, E Galea, G Morrone, MC Turco, V Martinelli, ... Leukemia 14 (5), 841-844, 2000 | 190 | 2000 |
| Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro P Tassone, P Tagliaferri, C Viscomi, C Palmieri, M Caraglia, ... British journal of cancer 88 (12), 1971-1978, 2003 | 187 | 2003 |
| Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells MF Romano, A Lamberti, P Tassone, F Alfinito, S Costantini, F Chiurazzi, ... Blood, The Journal of the American Society of Hematology 92 (3), 990-995, 1998 | 179 | 1998 |
| miR‐29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma‐related bone disease M Rossi, MR Pitari, N Amodio, MT Di Martino, F Conforti, E Leone, C Botta, ... Journal of cellular physiology 228 (7), 1506-1515, 2013 | 171 | 2013 |
| Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM) D Chauhan, P Neri, M Velankar, K Podar, T Hideshima, M Fulciniti, ... Blood 109 (3), 1220-1227, 2007 | 170 | 2007 |
| Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth E Leone, E Morelli, MT Di Martino, N Amodio, U Foresta, A Gullà, M Rossi, ... Clinical Cancer Research 19 (8), 2096-2106, 2013 | 167 | 2013 |
| Cytotoxic activity of the maytansinoid immunoconjugate B-B4–DM1 against CD138+ multiple myeloma cells P Tassone, VS Goldmacher, P Neri, A Gozzini, MA Shammas, ... Blood 104 (12), 3688-3696, 2004 | 163 | 2004 |
| In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2′-deacetyl-N2′-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells P Tassone, A Gozzini, V Goldmacher, MA Shammas, KR Whiteman, ... Cancer research 64 (13), 4629-4636, 2004 | 161 | 2004 |
| miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 N Amodio, MT Di Martino, U Foresta, E Leone, M Lionetti, M Leotta, ... Cell death & disease 3 (11), e436-e436, 2012 | 160 | 2012 |
| A clinically relevant SCID-hu in vivo model of human multiple myeloma P Tassone, P Neri, DR Carrasco, R Burger, VS Goldmacher, R Fram, ... Blood 106 (2), 713-716, 2005 | 151 | 2005 |
Pierosandro Tagliaferriprofessore di oncologia medica Università magna graecia di CatanzaroBestätigte E-Mail-Adresse bei unicz.it
